Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Elixirr delivers confident outlook after record first half

(Sharecast News) - Business consultancy Elixirr International has reported record interim results and reiterated its full-year forecasts, with the outlook bolstered by last week's acquisition of US strategy consultancy TRC. Elixirr, which transitions from AIM to the Main Market in July, said it delivered "significant outperformance" against the wider consulting market during the six months to 30 June.

The company reported a 35% year-on-year increase in revenues to £71.4m, with record revenues achieved in five of the six months during the period.

Results were helped by unlocking additional value from previous acquisitions, Elixirr said, with £14.7m of cross-sell revenue achieved in the first half, up 78% over last year.

Meanwhile, the number of £1m+ clients increased from 22 last year to 31.

Adjusted EBITDA surged 42% to £21.5m, helped by the adjusted EBITDA margin improving to 30% from 28.5%. Adjusted pre-tax profit was up 38% at £20.1m.

"As we broaden our market access through our growing client base and targeted acquisitions, we remain focused on helping our clients navigate their most critical challenges," said founder and chief executive Stephen Newton.

"With our acquisition of TRC Advisory, we are well-positioned to unlock even greater opportunities for our clients, shareholders and our team in the years ahead."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.